Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

There are two antibody-drug conjugates approved for the treatment of bladder cancer: sacituzumab govitecan (Trodelvy), which targets the Trop-2 protein on cancer cells, and enfortumab vedotin ...

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

Read more about A trial of sacituzumab govitecan for urothelial cancer (urinary tract ... A study of durvalumab and the vaccine S-488210/S-488211 for bladder cancer (DURANCE) This study is looking at ...

notably triple-negative breast and bladder cancer therapy Trodelvy (sacituzumab govitecan), which Gilead acquired as part of its $21 billion takeover of Immunomedics in 2020. Two of the three ...

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...